DBV Technologies Expands its Board of Directors with the Appointments of Claire Giraut and Maïlys Ferrere
(Thomson Reuters ONE) -
Press Release
Montrouge, France, June 21, 2016
DBV Technologies Expands its Board of Directors with the Appointments of Claire
Giraut and Maïlys Ferrere
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT), a clinical-stage specialty biopharmaceutical company, today announced the
appointment of Claire Giraut and Maïlys Ferrere to its Board of Directors,
effective immediately pursuant to their election at the Company's Annual General
Meeting in Montrouge, France. With these additions, DBV's Board now comprises
seven directors.
"We proudly welcome Claire and Maïlys, and we are pleased to have attracted such
professionals to our Board. These two appointments are an important step as we
continue to prepare for the launch of Viaskin Peanut as Claire and Maïlys bring
skills to our board that will support us in our transformation into a commercial
biopharmaceutical company," Said Dr. Pierre-Henri Benhamou, Chairman and CEO of
DBV Technologies." Dr. Benhamou continued, "Both appointments reflect our
commitment to long-term growth by adding complimentary expertise to our Board
with experienced board members like Claire and Maïlys. We believe they will both
help us continue building shareholder value."
Ms. Giraut will serve on the Board's Audit Committee. She is currently the Chief
Financial Officer of bioMérieux, a worldwide leader in in-vitro diagnostics. She
previously served notably as the Chief Financial Officer of Ipsen after holding
various finance leadership positions in other worldwide organizations. She also
serves since 2010 as a Director of Julius Baer Group Ltd. and Bank Julius Baer &
Co. Ltd., the leading Swiss private banking group. She holds a Masters from the
Institut National Agronomique (AgroParisTech) in Paris.
Ms. Claire Giraut said, "Over the years, I have been able to witness companies
like DBV grow into major transformational players in different industries, and
with its innovative technology and patient-driven strategy, DBV is poised to
change the lives of many people worldwide. I am truly looking forward to being
part of this team of talented individuals."
Ms. Mailys Ferrere is a Director, Head of the Large Venture Investment Activity
at Bpifrance, France's public investment bank, and DBV's second largest
shareholder. She graduated from Institut d'Etudes Politiques Paris, and began
her career in 1985 with the General Inspectorate of Société Générale before
working for multiple French banks in the Equity Capital Markets Origination
department. Mailys has been an observer in DBV's Board of Directors since the
Initial Public Offering of the Company in the Euronext in March 2012
"It has been a pleasure to see DBV's growth over the years, and we are proud to
have been one of the initial shareholders of the Company. It is this kind of
stories that make our jobs at BPI rewarding, as we help small French companies
become the leaders of tomorrow," commented Ms. Maïlys Ferrere.
About DBV Technologies
DBV Technologies developed Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on epicutaneous
immunotherapy, or EPIT®, DBV's method of delivering biologically active
compounds to the immune system through intact skin. With this new class of self-
administered and non-invasive product candidates, the company is dedicated to
safely transforming the care of food allergic patients, for whom there are no
approved treatments. DBV's food allergies programs include ongoing clinical
trials of Viaskin Peanut and Viaskin Milk, and preclinical development of
Viaskin Egg. DBV is also pursuing a human proof concept clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring
potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY.
Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global
Select Market in the form of American Depositary Shares (each representing one-
half of one ordinary share) (Ticker: DBVT). For more information on DBV
Technologies, please visit our website: www.dbv-technologies.com
Forward Looking Statements
This press release contains forward-looking statements, including statements
reflecting management's expectations for future financial and operational
performance and business outlook; and statements regarding our research and
development efforts and the commercial potential of our product candidates
generally. These forward-looking statements are not promises or guarantees and
involve substantial risks and uncertainties. Among the factors that could cause
actual results to differ materially from those described or projected herein
include uncertainties associated generally with research and development,
clinical trials and related regulatory reviews and approvals, the risk that
historical preclinical results may not be predictive of future clinical trial
results, and the risk that historical clinical trial results may not be
predictive of future trial results. A further list and description of these
risks, uncertainties and other risks can be found in the Company's regulatory
filings with the French Autorité des Marchés Financiers, the Company's
Securities and Exchange Commission filings and reports, including in the
Company's Annual Report on Form 20-F for the year ended December 31, 2015 and
future filings and reports by the Company. Existing and prospective investors
are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. DBV Technologies undertakes no
obligation to update or revise the information contained in this Press Release,
whether as a result of new information, future events or circumstances or
otherwise.
DBV Technologies Contact
Susanna Mesa
Senior Vice President, Strategy
+1 212-271-0861
susanna.mesa(at)dbv-technologies.com
Media Contacts
Erinn White, Centron PR
+1 646-722-8822
ewhite(at)centronpr.com
Media Contacts, Europe
Caroline Carmagnol, Alize RP - Relation Presse
+33 (0)6 64 18 99 59
caroline(at)alizerp.com
PDF Version:
http://hugin.info/156437/R/2022271/751334.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
[HUG#2022271]
Unternehmensinformation / Kurzprofil:
Datum: 21.06.2016 - 22:30 Uhr
Sprache: Deutsch
News-ID 479251
Anzahl Zeichen: 7917
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 223 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies Expands its Board of Directors with the Appointments of Claire Giraut and Maïlys Ferrere"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
